Annual Report

Overview

The report highlights promising clinical progress in 2025, with six of eight CARMA-study patients showing complete metabolic response at one month. It also records a successful rights issue bringing in 54.6 MSEK before issue costs, strengthening funding for continued development. ELC-100 received U.S. Orphan Drug Designation for pancreatic neuroendocrine tumors, while ELC-401 received a patent grant in Japan.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services